首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families
【24h】

Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families

机译:CLL家族中亲属单克隆B细胞淋巴细胞增生的自然历史

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Chronic lymphocytic lymphoma (CLL) has one of the highest familial risks among cancers. Monoclonal B-cell lymphocytosis (MBL), the precursor to CLL, has a higher prevalence (13%-18%) in families with 2 or more members with CLL compared with the general population (5%-12%). Although, the rate of progression to CLL for high-count MBLs (clonal B-cell count >= 500/mL) is similar to 1% to 5%/y, no low-count MBLs have been reported to progress to date. We report the incidence and natural history of MBL in relatives from CLL families. In 310 CLL families, we screened 1045 relatives for MBL using highly sensitive flow cytometry and prospectively followed 449 of them. MBL incidence was directly age- and sex-adjusted to the 2010 US population. CLL cumulative incidence was estimated using Kaplan-Meier survival curves. At baseline, the prevalence of MBL was 22% (235/1045 relatives). After a median follow-up of 8.1 years among 449 relatives, 12 individuals progressed to CLL with a 5-year cumulative incidence of 1.8%. When considering just the 139 relatives with low-count MBL, the 5-year cumulative incidence increased to 5.7%. Finally, 264 had no MBL at baseline, of whom 60 individuals subsequently developed MBL (2 high-count and 58 low-count MBLs) with an age- and sex-adjusted incidence of 3.5% after a median of 6 years of follow-up. In a screening cohort of relatives from CLL families, we reported progression from normal-count to low-count MBL to high-count MBL to CLL, demonstrating that low-count MBL precedes progression to CLL. We estimated a 1.1% annual rate of progression from low-count MBL, which is in excess of that in the general population.
机译:慢性淋巴细胞性淋巴瘤(CLL)是癌症中家族风险最高的一种。单克隆B细胞淋巴细胞增多症(MBL)是CLL的前体,与普通人群(5%-12%)相比,在有2名或更多CLL成员的家庭中有更高的患病率(13%-18%)。尽管高计数MBL(克隆性B细胞计数>=500/mL)进展至CLL的速度与1%至5%的年增长率相似,但迄今为止尚无低计数MBL进展的报道。我们报告了CLL家族亲属中MBL的发病率和自然史。在310个CLL家族中,我们使用高灵敏度流式细胞术筛查了1045名亲属的MBL,并对其中449人进行了前瞻性随访。MBL发病率与2010年美国人口的年龄和性别直接相关。使用Kaplan-Meier生存曲线估计CLL累积发病率。基线检查时,MBL的患病率为22%(235/1045名亲属)。449名亲属平均随访8.1年后,12名患者进展为CLL,5年累积发病率为1.8%。仅考虑139名低计数MBL的亲属,5年累积发病率上升至5.7%。最后,264人在基线检查时没有出现MBL,其中60人随后出现了MBL(2个高计数和58个低计数MBL),在中位随访6年后,年龄和性别调整后的发病率为3.5%。在CLL家族亲属的筛查队列中,我们报告了从正常计数到低计数MBL到高计数MBL到CLL的进展,证明低计数MBL先于CLL的进展。我们估计低计数MBL的年进展率为1.1%,高于一般人群。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号